Copegus and Hydroxyzine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Copegus (ribavirin) and Hydroxyzine (hydroxyzine hydrochloride). Common drug interactions include drug ineffective among females and rash among males.

The phase IV clinical study analyzes what interactions people have when they take Copegus and Hydroxyzine. It is created by eHealthMe based on reports of 38 people who take the same drugs from the FDA, and is updated regularly.

What is Copegus?

Copegus has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 15,115 Copegus users. Check the latest studies of Copegus.

What is Hydroxyzine?

Hydroxyzine has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 54,070 Hydroxyzine users. Check the latest studies of Hydroxyzine.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 22, 2026

38 people who take Copegus and Hydroxyzine together, and have interactions are studied.

Copegus and Hydroxyzine drug interactions.

What are the common drug interactions of Copegus and Hydroxyzine, by gender? *:

female:

  1. Drug ineffective
  2. Dysphagia (a condition in which swallowing is difficult or painful)
  3. Dyspnoea (difficult or laboured respiration)
  4. Feeling hot
  5. Hypotension (abnormally low blood pressure)
  6. Injection site erythema (redness at injection site)
  7. Injection site reaction
  8. International normalised ratio increased
  9. Lip ulceration (ulcer of lip)
  10. Memory impairment

male:

  1. Rash
  2. Loss of consciousness
  3. Bone pain
  4. Burning sensation
  5. Cataract (clouding of the lens inside the eye)
  6. Cold sweat
  7. Confusional state
  8. Cough
  9. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  10. Disorientation (disability in which the senses of time, direction, and recognition of people and places)

What are the common drug interactions of Copegus and Hydroxyzine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Dizziness
  2. Drug hypersensitivity
  3. Full blood count decreased
  4. Infected skin ulcer
  5. Infection
  6. Myalgia (muscle pain)
  7. Nausea (feeling of having an urge to vomit)
  8. Oral infection
  9. Rash
  10. Stomatitis (inflammation of mucous membrane of mouth)

50-59:

  1. Bradycardia (abnormally slow heart action)
  2. Pneumonia
  3. Septic shock (shock due to blood infection)
  4. Rash
  5. Fluid overload (too much fluid in the blood)
  6. Drug eruption (adverse drug reaction of the skin)
  7. Leukaemia (blood or bone marrow cancer)
  8. Panic attack
  9. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
  10. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)

60+:

  1. Anaemia (lack of blood)
  2. Infection
  3. Balance disorder
  4. Blood sodium decreased
  5. Chills (felling of cold)
  6. Constipation
  7. Diarrhoea
  8. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  9. Dizziness
  10. Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

  1. Itching: 6 people, 15.79%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 13.16%
  3. Insomnia (sleeplessness): 4 people, 10.53%
  4. Premenstrual Syndrome: 3 people, 7.89%
  5. Pain: 3 people, 7.89%
  6. Muscle Aches (muscle pain): 3 people, 7.89%
  7. Dysthymia (mild chronic depression): 3 people, 7.89%
  8. Drug Dependence: 3 people, 7.89%
  9. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 3 people, 7.89%
  10. Depression: 3 people, 7.89%

* Approximation only. Some reports may have incomplete information.

Do you take Copegus and Hydroxyzine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Copegus and Hydroxyzine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Copegus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Hydroxyzine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Copegus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydroxyzine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ribavirin and hydroxyzine hydrochloride (the active ingredients of Copegus and Hydroxyzine, respectively), and Copegus and Hydroxyzine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: